BioProject

We report the transcriptional changes associated with treatment of U2OS osteosarcoma cell line with DMSO, ND-09-QY33, CA-90-VK59, JC-68-AL90, MB-03-IE36, JC-43-ZO95, PA-33-CK45, KA-73-NB69, QC-05-UB63, SE-15-AV21, NV-67-DX31, DB-85-YA47, NA-37-JQ34, VA-76-OV33, & LD-22-SA99 Overall design: U2OS cells were treated with 3. More...

We report the transcriptional changes associated with treatment of U2OS osteosarcoma cell line with DMSO, ND-09-QY33, CA-90-VK59, JC-68-AL90, MB-03-IE36, JC-43-ZO95, PA-33-CK45, KA-73-NB69, QC-05-UB63, SE-15-AV21, NV-67-DX31, DB-85-YA47, NA-37-JQ34, VA-76-OV33, & LD-22-SA99 Overall design: U2OS cells were treated with 3.18nM, 10.04nM, 31.74nM, 100.29nM, 316.91nM, 1001.44nM, 3164.56nM, and 10000nM of DMSO, ND-09-QY33, CA-90-VK59, JC-68-AL90, MB-03-IE36, JC-43-ZO95, PA-33-CK45, KA-73-NB69, QC-05-UB63, SE-15-AV21, NV-67-DX31, DB-85-YA47, NA-37-JQ34, VA-76-OV33, & LD-22-SA99 for 24 hrs and subjected to DRUGseq Please note that a github repository has been created to assist in all downstream analysis: https://github.com/Novartis/DRUG-seq Less...